Will Canadian wildfire smoke impact air quality in Massachusetts? Here's the latest forecast.
Smoke from Canadian wildfires is headed toward Massachusetts, and prompting concerns about air quality in Boston.
There are numerous wildfires raging in northwestern Canada and also over parts of the southeastern United States.
Over the next few days, upper level winds will direct both smoke plumes toward New England.
WBZ-TV graphic
CBS Boston
Haze from these wildfires is appearing on visible satellite imagery over parts of the Upper Midwest, New York and Pennsylvania.
Over the next 24-48 hours, winds will funnel that smoke into the Boston area, creating a very hazy, brownish sky at times on Wednesday and Thursday.
It appears the thickest haze will be across western and northern New England; however, just about all of us will notice some fading of the sunshine.
WBZ-TV graphic
CBS Boston
Boston air quality
We do not anticipate air quality levels getting too bad here in southern New England given that the majority of the smoke will be aloft or above ground level.
Currently, air quality in most of the Upper Midwest is just considered "moderate." You have to go all the way to Minnesota before you run into any serious air quality issues.
On Tuesday, the air quality rating for Boston was good.
Hot weather in the forecast
We expect the hottest and most uncomfortable air of the season in Massachusetts on Wednesday and Thursday..
High temperatures on Wednesday will range between 85-90 degrees across most of the area (away from the South Coast).
On Thursday, we expect widespread 90-degree readings for the first time in 2025.
WBZ-TV graphic
CBS Boston
Dewpoints will climb well into the 60s, making it feel quite soupy outdoors.
Another rainy weekend in Massachusetts?
Pop quiz: What does the first week of June have in common with April and May? If you answered rainy Saturdays, you would be correct.
This is getting downright ridiculous. Assuming it rains this Saturday, which as of now looks awfully suspicious, that will make 12 consecutive Saturdays with rain falling in parts of southern New England.
On Friday, a cold front will arrive, bringing with it a change in wind direction as well as some showers and thunderstorms. Probably not the news you wanted to hear heading into the weekend, but at least it will serve to clear out the wildfire smoke from our area.
This frontal boundary will be very slow to move through New England and in fact, may stall out through Saturday. Thus, for the 12th week in a row, we are forecasting periods of showers and storms across the area on Saturday. As we get closer, we will get you some more precise timing and impacts.
For now, if you have the option, consider sliding the outdoor activities to Sunday ... again.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
Mick Abel gives the Phillies some stability amid the chaos in Toronto
TORONTO — By the end of it, there was chaos everywhere — concern for J.T. Realmuto after taking a foul ball to his groin, further consternation about Jordan Romano's place in all of this, and lament for a failed bases-loaded opportunity in the middle of the game. And, in the corner of the visitors clubhouse at Rogers Centre after a 2-1 loss to the Toronto Blue Jays, Mick Abel represented something stable for the Phillies. Advertisement No pitcher in 125 years of Major League Baseball had begun his career with two starts that consisted of at least five innings, no walks and one or zero runs allowed. Abel did it. He did not throw with the massive adrenaline bump he experienced during his big-league debut last month. But he pitched into the sixth. 'I wouldn't say I had my greatest stuff today,' Abel said. 'I didn't have my A-plus stuff today. So, going as long as I did and feeling how I did, I think I did a pretty good job.' That was something; the Phillies needed something because there was too much to digest. Realmuto was in serious pain during the ninth inning and had to leave. The team did not provide any updates on the severity of Realmuto's injury; the catcher was seen gingerly walking in the clubhouse afterward. The delay only intensified the ninth-inning drama. Jeff Hoffman, who went from the Phillies to the Blue Jays in the offseason, earned the win by getting the final out in the top of the ninth. Romano, the native Canadian son jettisoned by the Blue Jays, took the loss for the Phillies when Alejandro Kirk crushed a 97 mph fastball off the wall for a run-scoring single. Romano, who had spent more than 30 minutes before Wednesday's game acknowledging various Blue Jays fans who welcomed him back, hunched over on the mound. He put his hands on his knees as his former Toronto teammates celebrated on the infield. It was too poetic. 'Definitely a lot of emotion coming here,' Romano said. 'Got on the mound focused. I felt good. Stuff felt good. Obviously, not good enough.' Without his best stuff, Abel survived. He is here to stay — perhaps longer than expected. The Phillies created a rotation opening by shifting Taijuan Walker to the bullpen. Abel will have a spot so long as Aaron Nola is sidelined, and there is a chance Nola's absence will be extended. The Phillies paused plans for Nola to throw a live session to hitters Thursday afternoon at Rogers Centre because he felt soreness in his right side. 'Very mild,' Phillies manager Rob Thomson said. Nola described the decision to halt his throwing program as 'precautionary' and did not express much concern. Advertisement But he is going to need more time. Nola said his injured right ankle is feeling much better. But he's also been sick; an illness has spread through the clubhouse. Nola could need two minor-league rehab outings whenever he reaches that point in his recovery. That means more runway for Abel. 'I think it's the same thing,' Abel said. 'My job is to go out there and pitch every fifth day. And if that changes, that changes. I'm going to do the same thing every day throughout the week in order to prepare for those starts. Mentally, I think I'm in a really good spot right now. Not trying to ride the highs too high or really lull in the lulls. It's just trying to stay neutral the whole time.' Abel pitched Wednesday on four days' rest, only the second time in his professional career he has done that. The Phillies planned for him to have an extra day, but Zack Wheeler left the team to be with his wife, who is expecting this week. The team is unsure when Wheeler will make his next start; if he's not ready by Saturday, they will have to do a bullpen game. Knowing that Abel was in uncharted water, the Phillies did not plan to push him. But he kept throwing strikes; he fired first-pitch ones to 13 of the 19 batters he faced. Abel has yet to walk a batter in the majors. His 11 1/3 innings without a walk are the longest to begin a Phillies career since Carlton Loewer went 12 walkless innings in 1998. He began the sixth inning at 66 pitches. His command wavered. He allowed a one-out single to Andrés Giménez. Thomson let Abel face Bo Bichette for a third time. Bichette worked a 3-0 count, then took a huge hack at a 92 mph sinker. Brandon Marsh could not reach it in the left-center field gap. It was a run-scoring triple — the first big-league run Abel allowed. That ended his night. He has shown more conviction on the mound than the Phillies could have imagined. 'It's kind of clicked for him, you know?' Thomson said. 'He's been around now for a few years, and I think he's learned a lot. He's confident in his stuff. He understands now to attack hitters and trust his stuff, and that goes a long way.' There would have been less scrutiny on Romano in the ninth had the Phillies scored more runs. They missed a great chance in the fifth when Bryson Stott popped out and Trea Turner flied out with the bases loaded. The bullpen held — Orion Kerkering, Matt Strahm and Tanner Banks preserved the tie. If anything, the Phillies are worried about Romano having a backbreaking weakness. Opponents have stolen nine bases against him this season, already tied for Romano's season high. The Blue Jays know him well; they were going to exploit it. Vladimir Guerrero Jr., who had two steals since the beginning of last season, took second base on Romano despite the pitcher trying a slide-step delivery. Advertisement He was still too slow. 'It's kind of part of Jordy's game a little bit; you can see him try to be a little bit quicker,' Toronto manager John Schneider said. 'We talked about that with him for a long time. Good job by Vlad recognizing it.' Thomson said Romano has improved his times to the plate. 'But, still, we have ways to go here,' Thomson said. Is it something Romano can fix? 'I hope so,' Thomson said. 'Yeah.' Quality starting pitching fixes most things. Abel's performance was not the eye-popping type from his debut, but it was just as impressive given the circumstances. He is, for now, one less thing to stress. 'Just trying to go out there and win,' Abel said. 'It's the most important thing. I don't know if it's really a mentality shift or what. But I've felt good.'
Associated Press
an hour ago
- Associated Press
Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
First-in-class agent targets WISP1 in patients with IPF Primary endpoint in WISPer trial is change in Forced Vital Capacity (FVC) at 24 Weeks BOSTON, June 5, 2025 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 WISPer clinical trial evaluating MTX-463, an investigational therapy for idiopathic pulmonary fibrosis (IPF). The study's primary endpoint is the change from baseline in forced vital capacity (FVC)—an important measure of lung function—at 24 weeks. The study aims to advance the development of a potential novel treatment for patients living with IPF, and targets the myofibroblast, the key pathogenic cell in fibrosis. Mediar recently entered into a global licensing agreement with Lilly to advance MTX-463 through the Phase 2 WISPer trial. IPF is a rare and progressive lung disease characterized by scarring and thickening of lung tissue, which leads to increasing shortness of breath and a persistent dry cough. Despite available treatments, there remains a high unmet medical need, with an average life expectancy of three to five years post-diagnosis. The WISPer trial is a randomized, double-blind, placebo-controlled 24-week Phase 2 study designed to evaluate the efficacy, safety, and tolerability of MTX-463 in patients living with IPF. 'Dosing the first patient in the WISPer trial represents an important step forward in the pursuit of new options to address the urgent needs of individuals living with IPF,' said Toby Maher, MD, PhD, Director of Interstitial Lung Disease, University of Southern California, and lead investigator in the Phase 2 clinical study. 'IPF is a devastating disease with limited treatment options. We are eager to evaluate the potential of MTX-463 to slow or halt disease progression and look forward to the insights this study will provide for patients and their physicians.' 'Today marks an important milestone in our ongoing commitment to pioneering novel therapies to impact people living with fibrotic diseases. We extend our gratitude to Dr. Ryan Klein and the dedicated team at NewportNativeMD whose expertise and collaboration have been instrumental in reaching this important step,' said Jeff Bornstein, MD, Chief Medical Officer, Mediar. 'The first patient dosed with this first-in-class anti-fibrotic marks the beginning of a new chapter in our research, and we look forward to working with our clinical sites as we continue to enroll the Phase 2 program.' Mediar is also independently advancing its two wholly owned programs to treat other fibrotic disorders. MTX-474, a first-in-class human IgG1 antibody designed to neutralize EphrinB2 signaling, recently completed its Phase 1 clinical study. Mediar anticipates initiating a Phase 2 trial for MTX-474 in systemic sclerosis in the second half of 2025. Mediar's third novel fibrosis program, targeting SMOC2 for renal fibrosis, is also advancing with a plan to nominate a clinical candidate in the first half of 2025. About MTX-463 MTX-463 is a first-in-class human IgG1 antibody developed against WNT1-inducible signaling pathway protein-1 (WISP1). WISP1 is a secreted matricellular protein shown to have a relevant role in fibrosis progression, is measurable in human blood, and correlates with disease severity. Data indicates that MTX-463 neutralizes WISP1-mediated fibrotic signaling and significantly reduced fibrosis in vitro and in various preclinical models. A Phase 1 study was recently completed and a Phase 2 study in patients with IPF is now open (NCT06967805). More information can be found at: About Mediar Therapeutics Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar's goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach. For more information, contact [email protected] or follow us on LinkedIn. Media Contact [email protected] View original content to download multimedia: SOURCE Mediar Therapeutics
Associated Press
an hour ago
- Associated Press
Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual General and Special Meeting ('AGSM') to take place on Wednesday, June 11 th, 2025 at 4:30 pm ET at the Company's head office located at 41 Hollinger Road, Toronto, Ontario, Canada. In order to help make the AGSM more interactive for those shareholders, who are unable to attend in person, immediately after the formal part of the AGSM has concluded, Theralase® will be hosting a virtual presentation at 5:15 pm ET, which will include a corporate presentation of the Company's strategic objectives for 2025 and 2026, as well as a question and answer period to provide an opportunity for shareholders to have their questions addressed. The corporate power point presentation and question and answer period will end at 6:30 pm ET. Zoom Meeting Link: Webinar ID: 871 7513 9183 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom. An archived version will be available on the website, the next business day, following the conference call. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
